First patient treated in Takeda’s phase 3 trial for alpha-1 antitrypsin deficiency

Arrowhead Pharmaceuticals announced that the first patient has been treated in Takeda Pharmaceuticals’ phase 3 clinical trial of fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver disease.Fazirsiran, an investigational RNA interference therapy intended to reduce the production of the mutant alpha-1 antitrypsin protein, was co-developed by both Takeda and Arrowhead. The drug was first granted FDA orphan drug status for the treatment of alpha-1 antitrypsin deficiency in 2018 and later gained breakthrough therapy designation in 2021.The phase 3 REDWOOD clinicalRead More